Efficacy and safety of AZD3199, an inhaled ultra long-acting β2-agonist, in patients with COPD
Piotr Kuna, Yavor Ivanov, Vasily Trofimov, Ola Beckman, Thomas Bengtsson, Carin Jorup, Francois Maltais
European Respiratory Journal 2011 38: p868; DOI:
Piotr Kuna
1Autonomous Public Healthcare Unit, Barlicki University Hospital, Lodz, Poland
Yavor Ivanov
2Dept of Pulmonology, Medical University Pleven, Pleven, Bulgaria
Vasily Trofimov
3Department of Hospital Therapy, Pavlov State Medical University, St. Petersburg, Russian Federation
Ola Beckman
4Research and Development, AstraZeneca R&D, Lund, Sweden
Thomas Bengtsson
4Research and Development, AstraZeneca R&D, Lund, Sweden
Carin Jorup
4Research and Development, AstraZeneca R&D, Lund, Sweden
Francois Maltais
5Centre de Pneumologie, Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec, Canada
Vol 38 Issue Suppl 55
Table of Contents
Efficacy and safety of AZD3199, an inhaled ultra long-acting β2-agonist, in patients with COPD
Piotr Kuna, Yavor Ivanov, Vasily Trofimov, Ola Beckman, Thomas Bengtsson, Carin Jorup, Francois Maltais
European Respiratory Journal Sep 2011, 38 (Suppl 55) p868;